Andarine
S-4 · GTx-007
Half-life
4 hr
Time to Peak
1 hr
Steady State
~1 days
Dose Range
12.5–50 mg
Frequency
Twice daily
Overview
First-generation non-steroidal SARM developed by GTx Inc. Known for dose-dependent visual disturbances (yellow tint to vision, difficulty adjusting to darkness) caused by off-target binding to retinal receptors. These visual effects are reversible upon discontinuation. Less potent than newer SARMs (ostarine, LGD-4033) but still used in the community for cutting cycles at 25-50mg/day. Short half-life requires split dosing. Harm reduction: Start low to assess visual side effects. Split dose AM/PM due to short half-life. Suppresses testosterone moderately.
Mechanism of Action
Selectively binds androgen receptors in muscle and bone. First-generation SARM with less tissue selectivity than newer compounds — off-target retinal AR binding causes visual side effects. Partial agonist activity.
Dosing Information
| Route | Dose Range | Half-life | Tmax | Frequency |
|---|---|---|---|---|
| Oral | 12.5–50 mg | 4 hr | 1 hr | Twice daily |
Storage & Handling
Room temperature — Store at 20-25C. Protect from moisture and light.
Used in Regimens
Andarine is not currently part of any catalog regimen.
Related Tools
Track Andarine with Doseline
Reminders, medication level charts, injection site rotation, and protocol tracking — all free, all private.
Join the waitlistDoseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.